Overview

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2035-12-01

Target enrollment:

Participant gender:

Summary

This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.

Phase:

PHASE2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Pfizer

Treatments:

Bortezomib
daratumumab
Dexamethasone
Injections
Lenalidomide